Ocumetics Accelerates Toward Group Two First-In-Human Study with Manufacturing Launch of Optimized Accommodating Lens

(TheNewswire)

KeyHighlights

• Precision molds received for manufacturing of newoptimized accommodating intraocular lenses 

• Production and testing of next-generation lenses nowunderway 

• New lens design incorporates insights from Group OneFirst-in-Human study 

• Group Two preclinical surgeries targeted for early Q32026 

• FDA Investigational Device Exemption (IDE) preparationadvancing 

Calgary, Canada – TheNewswire -May 12, 2026 - Ocumetics Technology Corp.(“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF)(FRA: 2QBO), a developer of advanced vision restoration technologies,is pleased to announce a major development milestone in itsaccommodating intraocular lens program with the receipt of precisionmanufacturing molds and the launch of production and testing for itsnewly optimized accommodating intraocular lens (“OcumeticsLens”).

The milestone represents a significant transition fromearly clinical validation to refined product execution as Ocumeticsadvances toward expanded clinical studies and regulatorysubmissions.

The newly optimized Ocumetics Lens incorporatesvaluable surgical feedback, engineering refinements, and patientoutcome data collected during the Company’s Group One First-in-Humanstudy. These enhancements are designed to improve lens performance,manufacturing consistency, and long-term reliability.

A key advancement in the optimized lens architecture isthe elimination of dependency on fluid optical media such as air,water, or oil. By simplifying the lens design, Ocumetics believes itcan achieve greater predictability of lens movement within the eye,improved mechanical durability, and a more scalable, high-yieldmanufacturing process.

The Ocumetics Lens is being developed to restoredynamic focusing ability by working in harmony with the eye’snatural muscle movements, potentially allowing patients to achieveclear vision at multiple distances without glasses or contactlenses.

Development of the optimized lens was led by ChiefScientist Dr. Garth Webb in collaboration with Ocumetics’international engineering and manufacturing teams.

“I couldn’t be more impressed with the speed,skill, and innovation demonstrated by our scientific and engineeringteams,” said Dean Burns, President and CEO of Ocumetics. “The dataand experience gained from our Group One First-in-Human study havedirectly shaped our optimized lens design. With manufacturing nowunderway and a significantly simplified lens architecture, we believewe can accelerate development timelines while improving reliabilityand scalability.”

Ocumetics has initiated initial production runsalongside comprehensive validation testing focused on opticalperformance, mechanical movement, durability, and long-termfunctionality.

These activities are expected to support upcoming GroupTwo preclinical surgeries planned for early Q3 2026.  

The Company continues to advance toward key regulatorymilestones, including preparation for its planned InvestigationalDevice Exemption (“IDE”) submission to the U.S. Food and DrugAdministration.

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF)(FRA: 2QBO) is a Canadian research and product development companythat is dedicated to developing advanced vision correction solutionsthat enhance the quality of life for patients.  Through innovativeresearch and development, Ocumetics aims to transform the field ofophthalmology with state-of-the-art intraocular lenses and othervision-enhancing technologies.

Ocumetics is in the first-in-human early feasibilitystudy phase of a game-changing technology for the ophthalmic industry. Ocumetics has developed a dynamic intraocular lens that fits withinthe natural lens compartment of the eye, potentially to eliminate theneed for corrective lenses.  It is designed to allow the eye’snatural muscle activity to shift focus from distance to near,providing clear vision at all distances without the help of glasses orcontact lenses, and without perceptible time lag.  

FOR FURTHER INFORMATION, PLEASECONTACT:

David Burwell

Director, Investor Relations        

dave.burwell@ocumetics.com

(403) 410-7907

Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKINGINFORMATION: This news release includes certain “forward-lookingstatements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to,statements with respect to the commencement, timing and scope of theCorporation’s planned clinical trial program and other research anddevelopment activities and that they will be conducted as expected. Forward-looking statements are necessarily based upon a number ofestimates and assumptions that, while considered reasonable, aresubject to known and unknown risks, uncertainties, and other factorswhich may cause the actual results and future events to differmaterially from those expressed or implied by such forward-lookingstatements. Such factors include but are not limited to: operational matters, historical trends, currentconditions and expected future developments, access to financing aswell as other considerations that are believed to be appropriate inthe circumstances.  There can be no assurance that such statementswill prove to be accurate, as actual results and future events coulddiffer materially from those anticipated in such statements.Accordingly, readers should not place undue reliance onforward-looking statements.  The Corporation disclaims any intentionor obligation to update or revise any forward-looking statements,whether as a result of new information, future events or otherwise,except as required by law.

Copyright (c) 2026 TheNewswire - All rights reserved.